9-(4-aminobutyl)-1-methyl-9H-pyrido[3,4-b]indol-7-ol | 1342261-03-3

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 9-(4-aminobutyl)-1-methyl-9H-pyrido[3,4-b]indol-7-ol
• CAS: 1342261-03-3
• 化学式: C₁₆H₁₉N₃O
• 分子量: 269.346
• InChiKey: XFJGBZMERWQDBJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.94
• 重原子数：
  20.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  64.07
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  哈尔酚 在 sodium hydride 、 一水合肼 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 9-(4-aminobutyl)-1-methyl-9H-pyrido[3,4-b]indol-7-ol
  参考文献：
  名称：

  Structure–activity relationship study of beta-carboline derivatives as haspin kinase inhibitors

  摘要：

  Haspin is a serine/threonine kinase that phosphorylates Thr-3 of histone H3 in mitosis that has emerged as a possible cancer therapeutic target. High throughput screening of approximately 140,000 compounds identified the beta-carbolines harmine and harmol as moderately potent haspin kinase inhibitors. Based on information obtained from a structure-activity relationship study previously conducted for an acridine series of haspin inhibitors in conjunction with in silico docking using a recently disclosed crystal structure of the kinase, harmine analogs were designed that resulted in significantly increased haspin kinase inhibitory potency. The harmine derivatives also demonstrated less activity towards DYRK2 compared to the acridine series. In vitro mouse liver microsome stability and kinase profiling of a representative member of the harmine series (42, LDN-211898) are also presented. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.028

文献信息

• ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH
  申请人：OssiFi Inc.

  公开号：US20140288068A1

  公开（公告）日：2014-09-25

  In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula II, or Formula III. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease and cancer, using a compound of Formula I, Formula II, or Formula III.

  在一个方面，该发明提供了式I的化合物，以及其盐、水合物和异构体。在另一个方面，该发明提供了一种通过向需要的受试者投予式I、式II或式III的化合物的治疗有效剂量来促进骨形成的方法。本发明还提供了骨科和牙周设备，以及使用式I、式II或式III的化合物治疗肾脏疾病和癌症的方法。
• Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases
  申请人：Higgins Jonathan

  公开号：US20130231360A1

  公开（公告）日：2013-09-05

  The present disclosure is directed to compounds of Formula (I) which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.
• COMPOUNDS FOR BONE GROWTH
  申请人：OsteoQC, Inc

  公开号：US20170298059A1

  公开（公告）日：2017-10-19

  In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula II, or Formula III. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease and cancer, using a compound of Formula I, Formula II, or Formula III.
• US9540365B2
  申请人：——

  公开号：US9540365B2

  公开（公告）日：2017-01-10
• [EN] BETA-CARBOLINES AS INHIBITORS OF HASPIN AND DYRK KINASES<br/>[FR] BÊTA-CARBOLINES À TITRE D'INHIBITEURS DE KINASES HASPINE ET DYRK
  申请人：BRIGHAM & WOMENS HOSPITAL

  公开号：WO2011133795A2

  公开（公告）日：2011-10-27

  The present disclosure is directed to compounds of Formula ( I ) which are inhibitors of Haspin kinase and DYRK kinases. The compounds of the present disclosure, and compositions thereof, are useful in the treatment of disease related to Haspin kinase and DYRK kinase expression and/or activity.